Skip to content
  • About
    • CEO Comment
    • Story of Nanologica
    • Management team
    • Board of Directors
    • Career
    • Privacy policy
  • Chromatography
    • SVEA™ HPLC Columns
    • Preparative Chromatography
    • Catalogues / Brochures
    • Applications
    • Technical Support
    • Distributors
  • Drug Development
    • NLAB Silica™
    • NLAB Spiro™
    • Business model
    • Pipeline
    • Publications
  • Investor relations
    • Press releases
    • Financial reports
    • Calendar
    • Presentations
    • The Share
    • Rights Issue 2020
    • Corporate Governance
    • Subscribe
  • Latest news
  • Contact
Menu
  • About
    • CEO Comment
    • Story of Nanologica
    • Management team
    • Board of Directors
    • Career
    • Privacy policy
  • Chromatography
    • SVEA™ HPLC Columns
    • Preparative Chromatography
    • Catalogues / Brochures
    • Applications
    • Technical Support
    • Distributors
  • Drug Development
    • NLAB Silica™
    • NLAB Spiro™
    • Business model
    • Pipeline
    • Publications
  • Investor relations
    • Press releases
    • Financial reports
    • Calendar
    • Presentations
    • The Share
    • Rights Issue 2020
    • Corporate Governance
    • Subscribe
  • Latest news
  • Contact

RSS

Get RSS-feed

Fullständiga förslag till beslut för årsstämma 2020

  • May 14, 2020
  • News

Styrelsens förslag – Beslut om emissionsbemyndigande, Nanologica AB

Styrelsens förslag – Beslut om ändring av bolagsordningen, Nanologica AB

Aktieägarens Flerie Invest AB förslag – Beslut om incitamentsprogram för styrelsen, Nanologica AB

Styrelsens förslag – Beslut om incitamentsprogram för VD, ledning och övriga anställda, Nanologica AB

 

 

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Forskargatan 20 G
SE-151 36 Södertälje, Sweden

Email: info@nanologica.com
Tel: +46 (0)8 4107 4949

Subscribe

To subscribe to our press releases and financial reports, please enter your e-mail address:

About us

Nanologica is a nanotechnology company developing nanoporous silica particles for applications within life science. This competency is applied in two business areas – drug development and chromatography, a separation technique used in drug development and drug production. The Company’s mission is to contribute to providing better and cheaper treatments for patients worldwide, through the technology platform NLAB Silica™.

© Nanologica 2021
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT